Compare AGBK & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGBK | OPK |
|---|---|---|
| Founded | 1999 | 2006 |
| Country | Brazil | United States |
| Employees | 5001 | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 921.2M |
| IPO Year | N/A | 2011 |
| Metric | AGBK | OPK |
|---|---|---|
| Price | $7.11 | $1.52 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 3 |
| Target Price | ★ $17.20 | $1.60 |
| AVG Volume (30 Days) | 336.7K | ★ 2.9M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $606,879,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $235.22 | $4.24 |
| P/E Ratio | $46.19 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.32 | $0.98 |
| 52 Week High | $12.21 | $1.61 |
| Indicator | AGBK | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 52.31 | 67.22 |
| Support Level | $6.98 | $1.48 |
| Resistance Level | $7.61 | $1.58 |
| Average True Range (ATR) | 0.33 | 0.06 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 53.94 | 65.97 |
AGI Inc is a technology-powered provider of specialized financial services in Brazil. It empowers clients to access their social security benefits, severance fund benefits, and public or private sector payrolls through secured lending solutions and complementary banking, credit and insurance products tailored as per client needs. The company has one operating segment related to the banking business. The Bank provides a standardized set of financial products and services exclusively to individuals, mainly focused on credit, including digital accounts, cards, payroll and personal loans, and insurance offered through partners.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.